title: Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial.
abstract: In the first field trial with synthetic malaria vaccine SPf66 in a large population naturally exposed to malaria, 9957 persons greater than 1 year old and residing on the Colombian Pacific coast received three doses of the vaccine. To evaluate vaccine safety, clinical observations were made 30 min and 48 h after each immunization. There were no adverse reactions in 95.7% of cases. In the 4.3% of cases with adverse reactions, local induration and erythema were the most frequent. In a randomly selected group of vaccinees, anti-SPf66 antibody titers were measured after the third dose: 93% of the vaccinees raised antibodies to SPf66. Among these, 55% had titers greater than 1:1600. These results demonstrate the safety and immunogenicity of the SPf66 vaccine in a large field trial.
authors.affiliation: Instituto de Inmunología, Hospital San Juan de Dios, Universidad Nacional de Colombia, Bogotá.
authors.forename: R
authors.initials: R
authors.lastname: Amador
authors.forename: A
authors.initials: A
authors.lastname: Moreno
authors.forename: L A
authors.initials: LA
authors.lastname: Murillo
authors.forename: O
authors.initials: O
authors.lastname: Sierra
authors.forename: D
authors.initials: D
authors.lastname: Saavedra
authors.forename: M
authors.initials: M
authors.lastname: Rojas
authors.forename: A L
authors.initials: AL
authors.lastname: Mora
authors.forename: C L
authors.initials: CL
authors.lastname: Rocha
authors.forename: F
authors.initials: F
authors.lastname: Alvarado
authors.forename: J C
authors.initials: JC
authors.lastname: Falla
mesh_terms: D000293:Adolescent; D000328:Adult; D000595:Amino Acid Sequence; D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis*; D001794:Blood Pressure; D015153:Blotting, Western; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis; D007223:Infant; D016778:Malaria, Falciparum / Q000517:prevention & control*; D008297:Male; D008969:Molecular Sequence Data; D010963:Plasmodium falciparum / Q000276:immunology*; D015800:Protozoan Proteins / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology*; D016052:Protozoan Vaccines / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology*; D011994:Recombinant Proteins; D014611:Vaccination / Q000009:adverse effects
chemical_list: D000913:Antibodies, Protozoan; D007074:Immunoglobulin G; D015800:Protozoan Proteins; D016052:Protozoan Vaccines; D011994:Recombinant Proteins; C066269:SPf66 protein, Plasmodium